China SXT Pharmaceuticals, Inc. Class A Ordinary Shares
Here’s whether China SXT Pharmaceuticals, Inc. Class A Ordinary Shares (SXTC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+1.67% over 10 days). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 17 — oversold; weak 1-year return of -100.0%; 3-month momentum negative (-97.0%); rising volume on a downtrend (distribution, 2.98x avg). Currently 100.0% off its 52-week high. Score: -5/7.
SXTC is trading below its 200-day MA ($73.07) — a key warning sign the longer-term trend is under pressure. An RSI of 17.0 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -100.0% compares to +16.5% for SPY (trailed the market by 116.4%). The current 100.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.